BioStock: Regulatory success for BioInvent in the US

The U.S. Food and Drug Administration has approved BioInvent’s Investigational New Drug application for the antibody BI-1607, which is being developed to enhance efficacy and overcome resistance to existing treatments for solid tumours. Now, the company, which has four different drug candidates in five clinical trials, can expand its ongoing phase I/IIa study of BI-1607 to also include patients in the US.

Read the article at biostock.se:

https://www.biostock.se/en/2022/11/regulatory-success-for-bioinvent-in-the-us/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/